

INPLASY202370097

doi: 10.37766/inplasy2023.7.0097

Received: 23 July 2023

Published: 23 July 2023

Corresponding author:

Yiqian Zeng

124137816@qq.com

Author Affiliation:

Zhuzhou Central Hospital.

Zeng, XB¹; Shen XB²; Liu Z³; Liu X⁴; Zhu XP⁵; Qiu EY⁶; Zeng YQ⁷.

ADMINISTRATIVE INFORMATION

Support - This research does not receive specific funding.

Review Stage at time of this submission - The review has not yet started.

Conflicts of interest - None declared.

INPLASY registration number: INPLASY202370097

Amendments - This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 23 July 2023 and was last updated on 23 July 2023.

INTRODUCTION

Review question / Objective To investigate the anticoagulation effect and risk of rivaroxaban in patients with COVID-19.

Condition being studied Patients with confirmed COVID-19 infection.

METHODS

Participant or population Patients with confirmed COVID-19 infection.

Intervention Rivaroxaban.

Comparator No or other anticoagulant drugs.

Study designs to be included Randomized controlled trials.

Eligibility criteria Randomized controlled trials of rivaroxaban anticoagulation in COVID-19 patients.

Information sources Embase, PubMed, Cochrane Library.

Main outcome(s) mortality, events of thrombotic events and bleeding.

Quality assessment / Risk of bias analysis the Cochrane risk-of-bias tool will be used.

Strategy of data synthesis Review Manager version 5.4 will be used.

Subgroup analysis Review Manager version 5.4 will be used.

Sensitivity analysis Review Manager version 5.4 will be used.

Country(ies) involved China.

Keywords rivaroxaban COVID-19.

Contributions of each author

- Author 1 - Yiqian Zeng
- Author 2 - Xiangbo Shen.
- Author 3 - Zhao Liu.
- Author 4 - Xing Liu.
- Author 5 - Xiaopeng Zhu.
- Author 5 - Eryue Qiu.
- Author 7 - Zeng YQ.